The dietary supplement melatonin does not improve the symptoms of cachexia in patients with advanced cancer, according to a study published online February 25 in the Journal of Clinical Oncology.

CatalYm today announced that the first patient has been dosed in the Phase 2/3 VINCIT trial (Visugromab IN Cachexia ...

CatalYm has commenced dosing the first subject in its Phase II/III VINCIT trial, assessing the safety and efficacy of its ...

Cancer cachexia robs patients of weight, muscle, and strength, undermining treatment success and quality of life. Experts now advocate for a multimodal approach—combining nutrition, exercise, and ...

Cancer cachexia is a multifactorial syndrome marked by a severe loss of body weight due primarily to the wasting of skeletal muscle and adipose tissue. This syndrome is often accompanied by systemic ...

Understanding the importance of using the right diagnostic criteria for cachexia is crucial, as it can significantly influence the health and survival of cancer patients. Maintaining good health and ...

Pfizer researchers say they are developing a drug that might counteract a condition that leads to the death of cancer patients within a year of its diagnosis. Photo by Stephanie Lecocq/EPA-EFE Sept.

Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at ...

A majority of people with advanced cancers endure cachexia, a muscle-, fat-, and organ-wasting condition that is currently incurable and can be life-threatening. Detecting and intervening early can ...

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the cancer cachexia therapeutics market and it is poised to grow by USD 568.85 million during 2019-2023, progressing at a CAGR of 6% during the ...